Equities researchers at Jefferies Financial Group assumed coverage on shares of City Therapeutics (NASDAQ:CTY – Get Free Report) in a report issued on Monday, Zacks reports. The brokerage set a “strong-buy” rating on the stock.
Several other research analysts have also recently weighed in on CTY. Oppenheimer initiated coverage on shares of City Therapeutics in a research report on Tuesday, November 10th. They issued an “outperform” rating and a $46.00 price objective for the company. Wall Street Zen raised City Therapeutics to a “hold” rating in a report on Saturday, October 24th. Stifel Nicolaus initiated coverage on City Therapeutics in a research report on Tuesday, November 10th. They issued a “buy” rating and a $34.00 price objective on the stock. Finally, Zacks Research initiated coverage on City Therapeutics in a research note on Wednesday, November 11th. They issued a “hold” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $37.33.
Read Our Latest Report on City Therapeutics
City Therapeutics Stock Down 6.2%
Shares of CTY stock opened at $16.98 on Monday. City Therapeutics has a 1 year low of $15.81 and a 1 year high of $23.88.
Insider Transactions at City Therapeutics
In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc bought 170,000 shares of the business’s stock in a transaction on Monday, October 19th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the transaction, the insider owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Nelsen bought 170,000 shares of City Therapeutics stock in a transaction dated Monday, October 19th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the purchase, the director directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. The trade was a 1.26% increase in their position. The disclosure for this purchase is available in the SEC filing.
About City Therapeutics
City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.
Further Reading
- Five stocks we like better than City Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
